William (Bill) Raich, Ph.D., former leader of Finnegan’s biotechnology and pharmaceutical practice group, represents innovative companies developing biologics, pharmaceuticals, medical devices, and diagnostics. As a patent lawyer with a doctorate in cellular and molecular biology, he focuses his practice on patent litigation, pre-litigation counseling, and contentious proceedings at the U.S. Patent and Trademark Office, applying his technical expertise and courtroom insight to develop simple, persuasive positions for clients.
Bill has substantial experience with traditional patent litigation in district court and arbitrations, as well as litigating under the Biologics Price Competition and Innovation Act and litigating Abbreviated New Drug Application cases. He also represents clients before the Patent Trial and Appeal Board of the USPTO, appearing as lead counsel in numerous proceedings. In addition to his contentious work, Bill performs client counseling and opinion work, primarily in areas related to biologics, pharmaceuticals, and DNA sequencing.
Bill has been recognized by multiple industry organizations and award programs for his leadership in patent litigation, including honors for general patent litigation and life sciences litigation. His contributions have also earned recognition as a top intellectual property practitioner in the Washington, DC area.
Bill served at the U.S. Court of Appeals for the Federal Circuit as a law clerk for the Honorable Randall R. Rader and the Honorable Jimmie V. Reyna. He has represented pro bono, including as lead counsel, multiple disabled veterans before the U.S. Court of Appeals for Veteran’s Affairs.
- Lead counsel for Illumina adverse to 10x and Roche in patent litigation involving single cell sequencing.
- Lead counsel for AbbVie and Allergan adverse to various generic pharmaceutical makers in Hatch-Waxman litigations involving treatments for migraine.The first case is scheduled for a bench trial in May 2027.
- Represents Intellia Therapeutics adverse to BlueAllele in patent litigation involving gene editing technology.BlueAlelle is seeking 71M in damages with a jury trial scheduled in January 2027.
- Represented Sarepta Therapeutics in patent litigations involving treatments for Duchenne Muscular Dystrophy, securing a $116M jury verdict.
- Represented AbbVie Inc. in Biologics Price Competition and Innovation (BPCIA) litigation related to Humira®.
- Represented patent owner in post grant review (PGR) challenge related to Skyrizi®.
- Appellate
- Intellectual Property
- Accounting
- Agriculture
- Aviation
- Automotive
- Banking
- Construction and materials
- Consumer goods and services
- Energy
- Financial services
- Fisheries and aquaculture
- Food and beverage
- Forestry
- Gaming
- Government and public policy
- Healthcare
- Industrials
- Insurance
- Investment management
- Media
- Mining
- Natural resources
- Oil and gas
- Pharmaceutical and life sciences
- Real estate
- Shipping
- Social infrastructure
- Technology and telecommunications
- Tourism
- Transport
- Utilities
- Other
- JD, cum laude, Georgetown University Law Center - 2007
- PhD, Cellular and Molecular Biology, University of Wisconsin, Madison - 1999
- BA, Biology, with distinction, Swarthmore College -1993
- Giles S. Rich American Inn of Court - 2010
- U.S. Patent and Trademark Office - 2003
- District of Columbia - 2008
- Virginia - 2006
- U.S. Court of Appeals, Federal Circuit - 2011
- U.S. District Court, E.D. Michigan - 2009
- Supreme Court of the United States